| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10817909 | Clinical Biochemistry | 2015 | 7 Pages |
Abstract
Endogenous NT- and CT-IGFBP-4 from ACS patients' plasma correspond to the PAPP-A-derived IGFBP-4 fragments and do not undergo any truncation, modification, or complex formation in the patients' blood. Because of the demonstrated intact state of the circulating IGFBP-4 fragments, the neo-epitope-specific immunoassays perform reliably, allowing further clinical validation of these novel biomarkers.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Biochemistry
Authors
Alexey A. Konev, Tatyana I. Smolyanova, Alexey V. Kharitonov, Daria V. Serebryanaya, Stanislav V. Kozlovsky, Andrey N. Kara, Evgeniya E. Feygina, Alexey G. Katrukha, Alexander B. Postnikov,